Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

UNC Researchers Found New Characters In Cancer Cells

October 22, 2014 1:47 pm | News | Comments

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. Read more...            

TOPICS:

PhosImmune, PureMHC Working Together on Cancer Immunotherapies

October 22, 2014 1:28 pm | News | Comments

PhosImmune Inc. and PureMHC LLC announced they have entered into a license and collaboration agreement to develop novel antibody-based immunotherapies designed to target cancers. Read more...

TOPICS:

Biogen Slides as MS Drug Linked to Inflammation

October 22, 2014 1:20 pm | News | Comments

Shares of Biogen Idec slumped 8% after the pharmaceutical said a patient who took its newest multiple sclerosis drug suffered a brain inflammation and later died. Read more...                            

TOPICS:
Advertisement

Taiho Receives FDA Fast Track for Cancer Treatment

October 22, 2014 1:14 pm | News | Comments

Taiho Oncology Inc. announced that the FDA granted Fast Track designation for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC). Read more...

TOPICS:

Third Point Urges Amgen to Consider Breakup

October 22, 2014 12:49 pm | News | Comments

A hedge fund run by a famed investor said it has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. Read more....               

TOPICS:

Study Finds Drugs Still in Recalled Supplements

October 22, 2014 11:48 am | by Lindsey Tanner, AP Medical Writer | News | Comments

Dietary supplements containing potentially dangerous prescription drug ingredients may still be for sale even years after safety recalls, a study found. Read more...                              

TOPICS:

Actavis Signs Option to Acquire Rhythm Subsidiary

October 22, 2014 10:24 am | News | Comments

Actavis plc, a leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, announced that Actavis has been granted an exclusive option to acquire Rhythm's wholly owned subsidiary, Rhythm Health Inc. Read more...

TOPICS:

12,000 Boxes of Pain Relief Tablets Are Being Recalled

October 22, 2014 10:20 am | News | Comments

12,000 boxes of pain relief tablets sold at are being recalled because the cartons contain a different medication that could cause allergic reactions. Read more...                 

TOPICS:
Advertisement

Improved Data Reveals Higher Global Burden of Tuberculosis

October 22, 2014 10:13 am | News | Comments

Recent intensive efforts to improve collection and reporting of data on tuberculosis (TB) are shedding new light on the epidemic, revealing that there are almost half a million more cases of the disease than previously estimated. Read more...

TOPICS:

Johnson & Johnson Announces New Spending Plan for Ebola Vaccine

October 22, 2014 10:05 am | News | Comments

Johnson & Johnson announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. Read more...                    

TOPICS:

Oramed Gets Positive Data From Oral Insulin Trial

October 22, 2014 10:03 am | News | Comments

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, reported positive top-line clinical results from its Phase 2a clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. Read more...

TOPICS:

Rho Awarded New Federal Contract

October 21, 2014 2:46 pm | News | Comments

Rho, a contract research organization (CRO) providing clinical research services in both the commercial and federal market, has been awarded the renewal of their existing federal contract with the National Institute of Dental and Craniofacial Research (NIDCR). Read more...

TOPICS:

Neurocrine Announces Phase 3 Study for Inhibitor

October 21, 2014 2:40 pm | News | Comments

Neurocrine Biosciences Inc. announced that it has initiated a Phase 3 clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854.  Read more...                    

TOPICS:

Researchers Demonstrate Advances in Creating Blood Cancer Treatment

October 21, 2014 2:33 pm | News | Comments

Researchers at NYU Langone Medical Center and elsewhere said that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. Read more...    

TOPICS:

Lilly's Diabetes Treatment Receives NDA

October 21, 2014 2:19 pm | News | Comments

FDA has accepted the filing of a NDA for empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination, an investigational compound being studied for the treatment of adults with type 2 diabetes (T2D). Read more...       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading